Value
8.8/10data confidence 83%| Component | Sub-score |
|---|---|
| P/S | 10.0 |
| EV/EBITDA | 5.5 |
| Fwd P/E | 9.7 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 7.3x
- ▸PEG: 0.04
- ▸Attractively valued
CE · Why this verdict
Why Celanese (CE) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company's underlying business quality falls materially short of minimum standards — with no competitive moat and quality concerns flagged across the financial profile — meaning the investment case depends on a fundamental business improvement rather than simply on the passage of time at a cheap price. Warnings | Piotroski F-Score rises above 7 for 2 consecutive quarters, signaling that the financial quality of the business has improved to a level consistent with a viable investment. | →Stable |
| CounterChemicals businesses are inherently cyclical and can exhibit depressed quality metrics at cycle troughs that recover sharply as volumes and pricing normalize; if the business is near a cyclical bottom, the current quality readings may systematically overstate structural weakness. | ||
At a forward price-to-earnings multiple of approximately 8 times and a PEG ratio near zero, the stock prices in severe fundamental impairment; if operations stabilize and earnings recover even modestly, the valuation gap to analyst consensus of roughly 25% represents meaningful upside optionality for patient investors. Valuation breakdown | Analyst consensus price target holds above $60 for 4 consecutive quarters and the forward multiple remains below 12 times, preserving the value margin of safety. | →Stable |
| CounterA cheap multiple in a structurally challenged chemicals business can persist or worsen; the supplier concentration through the Fairway joint venture adds an external constraint on the company's ability to fully capture a volume recovery even if end-market demand returns. | ||
The two most recent quarterly reports both missed consensus estimates — including a 26% miss in the prior quarter — establishing a recent pattern of deteriorating delivery that suggests either management has lost visibility into its own business or structural headwinds are compressing results faster than the Street anticipates. Earnings | EPS beats consensus by more than 5% for 2 consecutive quarters, confirming that earnings have stabilized and management has rebuilt forecast accuracy. | →Stable |
| CounterThe two older quarters within the same trailing four-quarter window both beat estimates, showing the miss pattern is recent rather than chronic; if the misses reflect transient volume softness tied to end-market destocking, a recovery in customer demand could quickly restore beat performance. | ||
Revenue has declined approximately 2% year-over-year, pointing to a business that is losing volume, pricing power, or both — a deteriorating revenue base that compounds the challenge of maintaining earnings and cash flows at levels that support even a modest valuation multiple. Growth breakdown | Revenue growth turns positive and exceeds 3% year-over-year for 2 consecutive quarters, confirming the contraction has reversed. | →Stable |
| CounterA forward PEG ratio near zero implies the market expects a material acceleration in earnings relative to current revenue; if the earnings recovery is margin-driven rather than volume-driven, revenue growth may lag earnings improvement significantly without undermining the investment thesis. | ||
The company's underlying business quality falls materially short of minimum standards — with no competitive moat and quality concerns flagged across the financial profile — meaning the investment case depends on a fundamental business improvement rather than simply on the passage of time at a cheap price.
→StableWarnings
- Expectation
- Piotroski F-Score rises above 7 for 2 consecutive quarters, signaling that the financial quality of the business has improved to a level consistent with a viable investment.
CounterChemicals businesses are inherently cyclical and can exhibit depressed quality metrics at cycle troughs that recover sharply as volumes and pricing normalize; if the business is near a cyclical bottom, the current quality readings may systematically overstate structural weakness.
At a forward price-to-earnings multiple of approximately 8 times and a PEG ratio near zero, the stock prices in severe fundamental impairment; if operations stabilize and earnings recover even modestly, the valuation gap to analyst consensus of roughly 25% represents meaningful upside optionality for patient investors.
→StableValuation breakdown
- Expectation
- Analyst consensus price target holds above $60 for 4 consecutive quarters and the forward multiple remains below 12 times, preserving the value margin of safety.
CounterA cheap multiple in a structurally challenged chemicals business can persist or worsen; the supplier concentration through the Fairway joint venture adds an external constraint on the company's ability to fully capture a volume recovery even if end-market demand returns.
The two most recent quarterly reports both missed consensus estimates — including a 26% miss in the prior quarter — establishing a recent pattern of deteriorating delivery that suggests either management has lost visibility into its own business or structural headwinds are compressing results faster than the Street anticipates.
→StableEarnings
- Expectation
- EPS beats consensus by more than 5% for 2 consecutive quarters, confirming that earnings have stabilized and management has rebuilt forecast accuracy.
CounterThe two older quarters within the same trailing four-quarter window both beat estimates, showing the miss pattern is recent rather than chronic; if the misses reflect transient volume softness tied to end-market destocking, a recovery in customer demand could quickly restore beat performance.
Revenue has declined approximately 2% year-over-year, pointing to a business that is losing volume, pricing power, or both — a deteriorating revenue base that compounds the challenge of maintaining earnings and cash flows at levels that support even a modest valuation multiple.
→StableGrowth breakdown
- Expectation
- Revenue growth turns positive and exceeds 3% year-over-year for 2 consecutive quarters, confirming the contraction has reversed.
CounterA forward PEG ratio near zero implies the market expects a material acceleration in earnings relative to current revenue; if the earnings recovery is margin-driven rather than volume-driven, revenue growth may lag earnings improvement significantly without undermining the investment thesis.
TrendMatrix Research · core thesis
Engine thesis — one sentence
A deeply discounted chemicals business trades at a forward multiple of approximately 8 times earnings with roughly 25% upside to analyst consensus, but below-minimum quality scores, two consecutive earnings misses, and declining revenue make this a speculative recovery play rather than a quality compounder.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 1.6 |
| Gross margin | 0.2 |
| Op margin | 3.4 |
| Net margin | 0.0 |
| Current ratio | 5.1 |
| Moat | 2.5 |
| Piotroski F | 4.4 |
- ▸No competitive moat
- ▸Quality concerns
Growth
6.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 2.0 |
| EPS growth | 10.0 |
- ▸Declining revenue: -2%
Momentum
2.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 1.2 |
| OBV | 1.0 |
| MA position | 2.2 |
| Volume | 3.0 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA but MA still rising (+1.6%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 3.8 |
| Analyst rating | 7.3 |
| Price target | 9.5 |
- ▸Analyst upside: 50%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.0 |
| quality rank | 1.5 |
| growth rank | 3.3 |
Technical
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.2 |
| support resistance | 7.2 |
| 52w position | 3.5 |
| gap | 5.0 |
Risk (lower is worse)
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.6 |
| days to cover | 6.2 |
| volatility | 0.9 |
| put call | 3.1 |
| implied vol | 0.0 |
| beta | 8.5 |
| debt equity | 2.1 |
| news risk | 6.0 |
- ▸Elevated put/call: 1.53
- ▸High IV: 81%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.1 |
| dividend safety | 5.2 |
| news activity | 6.0 |
- ▸Earnings concerns: 2B/2M
- ▸Dividend: 25.0%
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (5)
- ASYMMETRY:3.8>=1.5
- INSIDER:OK
- EARNINGS_PROXIMITY:31d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:2.2<4.5
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
3.75
Upside
+34.7%
Downside
9.3%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 8.8 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:2.2<4.5.
The strongest dimensions are Value at 8.8, Sentiment at 6.8, and Growth at 6.0; the weakest are Quality at 2.1, Momentum at 2.2, and Peer rank at 3.5. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 3.75 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Minimum Threshold
Trip ifPiotroski F-Score rises above 7 for 2 consecutive quarters.
- P2Consecutive Earnings Misses
Trip ifEPS beats consensus by more than 5% for 2 consecutive quarters.
- P3Revenue Contraction Trend
Trip ifRevenue growth turns positive and exceeds 3% year-over-year for 2 consecutive quarters.
- P4Deep Value Optionality
Trip ifForward P/E multiple expands above 15 times, compressing the margin of safety to less than 10% implied upside.